Feasibility study of Bismuth Subsalicylate (BSS) as an addition to standard of care for COVID-19 therapy

Mary Beth Yacyshyn, James Collins, Michelle Chua, Angela Siegwald, Sara Yacyshyn, Valerie Briones-Pryor, Bruce Yacyshyn, Mary Beth Yacyshyn, James Collins, Michelle Chua, Angela Siegwald, Sara Yacyshyn, Valerie Briones-Pryor, Bruce Yacyshyn

No abstract available

Keywords: Bismuth subsalicylate (BSS); SARS-CoV-2; helicase.

Figures

Figure 1
Figure 1
SARS-CoV-2 status on day 3 versus baseline health and medication status. (A) Baseline health scores. Baseline health scores were calculated by using the sum of the number of preexisting comorbidities + the number of baseline COVID–19-related 5 symptoms + number of COVID-19 morbidities. (B) The number of any existing home medications that patients were taking. Open symbols represent outpatients and closed symbols represent inpatients. Statistics were performed using Prism 9 for Mac OS (GraphPad Software, San Diego, California). Nonparametric Mann-Whitney P values were reported.

References

    1. Ledford H. COVID antiviral pills: what scientists still want to know. Nature. 2021 Nov;599(7885):358–359. doi: 10.1038/d41586-021-03074-5. PMID: 34759341.
    1. Gandhi M. The new COVID drugs are a bigger deal than people realize. Accessed March 29, 2022. .
    1. Gordon DE, Jang GM, Bouhaddou M, Xu J, Obernier K, White KM, O'Meara MJ, Rezelj VV, Guo JZ, Swaney DL, Tummino TA, Hüttenhain R, Kaake RM, Richards AL, Tutuncuoglu B, Foussard H, Batra J, Haas K, Modak M, Kim M, Haas P, Polacco BJ, Braberg H, Fabius JM, Eckhardt M, Soucheray M, Bennett MJ, Cakir M, McGregor MJ, Li Q, Meyer B, Roesch F, Vallet T, Mac Kain A, Miorin L, Moreno E, Naing ZZC, Zhou Y, Peng S, Shi Y, Zhang Z, Shen W, Kirby IT, Melnyk JE, Chorba JS, Lou K, Dai SA, Barrio-Hernandez I, Memon D, Hernandez-Armenta C, Lyu J, Mathy CJP, Perica T, Pilla KB, Ganesan SJ, Saltzberg DJ, Rakesh R, Liu X, Rosenthal SB, Calviello L, Venkataramanan S, Liboy-Lugo J, Lin Y, Huang XP, Liu Y, Wankowicz SA, Bohn M, Safari M, Ugur FS, Koh C, Savar NS, Tran QD, Shengjuler D, Fletcher SJ, O'Neal MC, Cai Y, Chang JCJ, Broadhurst DJ, Klippsten S, Sharp PP, Wenzell NA, Kuzuoglu-Ozturk D, Wang HY, Trenker R, Young JM, Cavero DA, Hiatt J, Roth TL, Rathore U, Subramanian A, Noack J, Hubert M, Stroud RM, Frankel AD, Rosenberg OS, Verba KA, Agard DA, Ott M, Emerman M, Jura N, von Zastrow M, Verdin E, Ashworth A, Schwartz O, d'Enfert C, Mukherjee S, Jacobson M, Malik HS, Fujimori DG, Ideker T, Craik CS, Floor SN, Fraser JS, Gross JD, Sali A, Roth BL, Ruggero D, Taunton J, Kortemme T, Beltrao P, Vignuzzi M, García-Sastre A, Shokat KM, Shoichet BK, Krogan NJ. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature. 2020 Jul;583(7816):459–468. doi: 10.1038/s41586-020-2286-9. Epub 2020 Apr 30. PMID: 32353859; PMCID: PMC7431030.
    1. Gil C, Ginex T, Maestro I, Nozal V, Barrado-Gil L, Cuesta-Geijo MÁ, Urquiza J, Ramírez D, Alonso C, Campillo NE, Martinez A. COVID-19: Drug Targets and Potential Treatments. J Med Chem. 2020 Nov 12;63(21):12359–12386. doi: 10.1021/acs.jmedchem.0c00606. Epub 2020 Jun 26. PMID: 32511912; PMCID: PMC7323060.
    1. Mishra SK, Tripathi T. One year update on the COVID-19 pandemic: Where are we now? Acta Trop. 2021 Feb;214 doi: 10.1016/j.actatropica.2020.105778. Epub 2020 Nov 28. PMID: 33253656; PMCID: PMC7695590.
    1. Brum JM, Gibb RD, Ramsey DL, Balan G, Yacyshyn BR. Systematic Review and Meta-Analyses Assessment of the Clinical Efficacy of Bismuth Subsalicylate for Prevention and Treatment of Infectious Diarrhea. Dig Dis Sci. 2020 Aug 8 doi: 10.1007/s10620-020-06509-7. Epub ahead of print. PMID: 32772204.
    1. Pitz AM, Park GW, Lee D, Boissy YL, Vinjé J. Antimicrobial activity of bismuth subsalicylate on Clostridium difficile, Escherichia coli O157:H7, norovirus, and other common enteric pathogens. Gut Microbes. 2015;6(2):93–100.
    1. Yuan S, Wang R, Chan JF, Zhang AJ, Cheng T, Chik KK, Ye ZW, Wang S, Lee AC, Jin L, Li H, Jin DY, Yuen KY, Sun H. Metallodrug ranitidine bismuth citrate suppresses SARS-CoV-2 replication and relieves virus-associated pneumonia in Syrian hamsters. Nat Microbiol. 2020 Nov;5(11):1439–1448. doi: 10.1038/s41564-020-00802-x. Epub 2020 Oct 7. PMID: 33028965.
    1. Shu T, Huang M, Wu D, Ren Y, Zhang X, Han Y, Mu J, Wang R, Qiu Y, Zhang DY, Zhou X. SARS-Coronavirus-2 Nsp13 Possesses NTPase and RNA Helicase Activities That Can Be Inhibited by Bismuth Salts. Virol Sin. 2020 Jun;35(3):321–329. doi: 10.1007/s12250-020-00242-1. Epub 2020 Jun 4. PMID: 32500504; PMCID: PMC7271831.
    1. Jiao L, Li H, Xu J, Yang M, Ma C, Li J, Zhao S, Wang H, Yang Y, Yu W, Wang J, Yang J, Long H, Gao J, Ding K, Wu D, Kuang D, Zhao Y, Liu J, Lu S, Liu H, Peng X. The Gastrointestinal Tract Is an Alternative Route for SARS-CoV-2 Infection in a Nonhuman Primate Model. Gastroenterology. 2021 Apr;160(5):1647–1661. doi: 10.1053/j.gastro.2020.12.001. Epub 2020 Dec 9. PMID: 33307034; PMCID: PMC7725054.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다